Psychosis and Clinical Outcomes in Alzheimer Disease: A Longitudinal Study

Grants

Funding Acknowledgements

The Dementia Collaborative Research Centre is funded by the National Health and Medical Research Council. Data collection was funded in part by Janssen-Cilag Pty Limited. Janssen-Cilag had no input into the design, execution, analysis, interpretation, or writing of this study. We are grateful to the staff at nine testing sites and the patients and their families who supported this study.In the last three years, DA has received grants/funds for clinical trials from Eli Lilly and PranaBio; honoraria from Lundbeck, Pfizer, and Servier; and royalties for edited books from Cambridge University Press and Hodder. He has also been a consultant for PranaBio's data safety monitoring board and attended advisory board meetings for Eli Lilly. MW has worked on drug trials funded by pharmaceutical companies including AbbiVie, Astra Zeneca, AZ therapies, Biogen, Buck, Eisai, Janssen, Lilly, Lundbeck, Merck/MSD, Novartis, Pfizer, Roche, Servier, Takeda, Tau Rx, vTv Therapeutics and Zinfandel. He has also received honoraria for consultancy or presentations at meetings organized by CogRx, Lundbeck, Merk Sharp & Dohme, Novartis, and Nutricia. HB has worked on drug trials for patients with mild cognitive impairment and Alzheimer's disease sponsored by Sanofi-Aventis, Servier and Tau Therapeutics. He has also been a consultant and/or advisory board member for Eli Lilly and Nutricia. MHC has no conflicts of interest to declare.